Advertisement

International Journal of Hematology

, Volume 105, Issue 4, pp 532–535 | Cite as

Dabigatran overdose: a case report of acute hepatitis. Extracorporeal treatment

  • Mariagrazia Porru
  • Antonella MameliEmail author
  • Maria E. Cianchetti
  • Mario Musu
  • Paola Schirru
  • Maria F. Ruberto
  • Doris Barcellona
  • Francesco Marongiu
Case Report

Abstract

Dabigatran is an oral, direct thrombin inhibitor approved by international regulatory agencies for stroke prevention in patients with paroxysmal or persistent non-rheumatic atrial fibrillation (AF). The benefits of dabigatran are widely described, but its use in the geriatric population is not without risk. Chronic kidney disease is a common comorbidity with AF, and thus frequent checks of renal function in elderly patients are recommended. We report a case of dabigatran intoxication in an elderly man affected by heart failure and worsening renal function, who developed acute hepatitis and coma, which was successfully treated with continuous veno-venous hemodiafiltration. Although extracorporeal therapy has been suggested as a strategy for clearing dabigatran during acute bleeding, this approach may be useful in other dabigatran-related, life-threatening conditions, such as that described in this report.

Keywords

Dabigatran etexilate Acute hepatitis Overdose Continuous veno-venous hemodiafiltration 

Notes

Acknowledgements

We thank Mr. Barry Mark Wheaton for his editing assistance.

References

  1. 1.
    Boehringer Ingelheim. Pradaxa Summary of Product Characteristics. European Medicines Agency. http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Product_Information/human/000829/WC500041059.pdf. Accessed 18 May 2016
  2. 2.
    Wallentin L, Yusuf S, Ezekowitz MD, Alings M, Flather M, Franzosi MG, et al. RE-LYinvestigators. Efficacy and safety of dabigatran compared with warfarin at different levels of international normalised ratio control for stroke prevention in atrial fibrillation: an analysis of the RE-LY trial. Lancet. 2010;376(9745):975–83.Google Scholar
  3. 3.
    Stangier J, Rathgen K, Stahle H, Mazur D. Influence of renal impairment on the pharmacokinetics and pharmacodynamics of oral dabigatran etexilate: an open-label, parallel group, single-centre study. Clin Pharmacokinet. 2010;49:259–68.CrossRefPubMedGoogle Scholar
  4. 4.
    Rochwerg B, Xenodemetropoulos T, Crowther M, Spyropoulos A. Dabigatran-induced acute hepatitis. Clin Appl Thromb Hemost. 2012;18:549–50.CrossRefPubMedGoogle Scholar
  5. 5.
    van Ryn J, Stangier J, Haertter S, Liesenfeld KH, Wienen W, Feuring M, et al. Dabigatran etexilate—a novel, reversible, oral direct thrombin inhibitor: interpretation of coagulation assays and reversal of anticoagulant activity. Thromb Haemost. 2010;103:1116–27.CrossRefPubMedGoogle Scholar
  6. 6.
    Heidbuchel H, Verhamme P, Alings M, Antz M, Hacke W, Oldgren J, et al. European Heart Rhythm Association practical guide on the use of new oral anticoagulants in patients with nonvalvular atrial fibrillation. Europace. 2013;15:625–51.CrossRefPubMedGoogle Scholar
  7. 7.
    Baglin T, Hillarp A, Tripodi A, Elalamy I, Buller H, Ageno W. Measuring oral direct inhibitors (ODIs) of thrombin and factor Xa: a recommendation from the Subcommittee on Control of Anticoagulation of the Scientific and Standardisation Committee of the International Society on Thrombosis and Haemostasis. J Thromb Haemost. 2013;11:756–60.CrossRefGoogle Scholar
  8. 8.
    Pollack CV Jr, Reilly PA, Eikelboom J, Glund S, Verhamme P, Bernstein RA, et al. Idarucizumab for dabigatran reversal. N Engl J Med. 2015;373:511–20.CrossRefPubMedGoogle Scholar
  9. 9.
    Blech S, Ebner T, Ludwig-Schwellinger E, Stangier J, Roth W. The metabolism and disposition of the oral direct thrombin inhibitor, dabigatran, in humans. Drug Metab Dispos. 2008;36:386–99.CrossRefPubMedGoogle Scholar
  10. 10.
    Bouchard J, Ghannoum M, Bernier-Jean A, Williamson D, Kershaw G, Weatherburn C, et al. Comparison of intermittent and continuous extracorporeal treatments for the enhanced elimination of dabigatran. Clin Toxicol (Phila). 2015;53:156–63.CrossRefGoogle Scholar
  11. 11.
    Claisse G, Delavenne X, Masson I, Maillard N, Alamartine E, Mariat C. Venovenous haemodiafiltration for the management of dabigatran overdose in intensive care unit. Clin Kidney J. 2015;8:199–201.CrossRefPubMedPubMedCentralGoogle Scholar
  12. 12.
    Chang DN, Dager WE, Chin AI. Removal of dabigatran by hemodialysis. Am J Kidney Dis. 2013;61:487–9.CrossRefPubMedGoogle Scholar
  13. 13.
    Artunc F, Muehlbacher T, Baumann D, Birschmann I, Kuhn J, Heyne N, et al. Removal of dabigatran is superior by sustained low efficient dialysis (SLED) compared to intermittent hemodialysis. Blood Purif. 2015;39:331–2.CrossRefPubMedGoogle Scholar
  14. 14.
    Singh T, Maw TT, Henry BL, Pastor-Soler NM, Unruh ML, Hallows KR, et al. Extracorporeal therapy for dabigatran removal in the treatment of acute bleeding: a single center experience. Clin J Am Soc Nephrol. 2013;8:1533–9.CrossRefPubMedPubMedCentralGoogle Scholar

Copyright information

© The Japanese Society of Hematology 2016

Authors and Affiliations

  • Mariagrazia Porru
    • 1
  • Antonella Mameli
    • 1
    Email author
  • Maria E. Cianchetti
    • 1
  • Mario Musu
    • 2
  • Paola Schirru
    • 1
  • Maria F. Ruberto
    • 1
  • Doris Barcellona
    • 1
  • Francesco Marongiu
    • 1
  1. 1.Internal Medicine and Haemocoagulopathies UnitAzienda Ospedaliero Universitaria (A.O.U.), Presidio “Duilio Casula”, University of CagliariMonserratoItaly
  2. 2.Intensive Care UnitAzienda Ospedaliero Universitaria (A.O.U.), Presidio “Duilio Casula”, University of CagliariMonserratoItaly

Personalised recommendations